Table 3. Changes in glycosylated hemoglobin after 12 weeks of treatment with sodium-glucose cotransporter-2 inhibitors as add-on therapy and switch therapy.
| Variable | Baseline | Week 12 | LS mean change from baseline (95% CI) | Difference in LS mean change (95% CI)a |
|---|---|---|---|---|
| Add-on therapy | ||||
| Overall (n=207) | 8.6±0.1 | 7.6±0.1 | −0.94 (−1.05 to −0.83)b | |
| MET (n=58) | 7.8±0.1 | 7.0±0.1 | −1.20 (−1.39 to −1.02)b | - |
| MET+SU (n=19) | 8.1±0.2 | 7.1±0.1 | −1.16 (−1.46 to −0.86)b | −0.05 (−0.51 to 0.42) |
| MET+SU+DPP4i (n=52) | 8.9±0.2 | 7.7±0.1 | −1.06 (−1.25 to −0.88)b | −0.14 (−0.50 to 0.22) |
| Insulin (n=78) | 9.0±0.1 | 8.1±0.1 | −0.71 (−0.86 to −0.56)b | −0.49 (−0.84 to −0.15)c |
| Switch therapy | ||||
| Overall (n=203) | 8.4±0.1 | 8.0±0.1 | −0.42 (−0.53 to −0.30)b | |
| DPP4i (n=114) | 8.2±0.1 | 8.0±0.1 | −0.33 (−0.50 to −0.16)b | - |
| SU (n=54) | 8.7±0.2 | 8.2±0.2 | −0.42 (−0.67 to −0.18)b | 0.09 (−0.28 to 0.46) |
| TZD (n=35) | 8.3±0.1 | 7.9±0.2 | −0.44 (−0.74 to −0.13)b | 0.11 (−0.32 to 0.53) |
Values are presented as mean±standard error.
LS, least square; CI, confidence interval; MET, metformin; SU, sulfonylurea; DPP4i, dipeptidyl peptidase 4 inhibitor; TZD, thiazolidinedione.
aDifference in the LS mean change, which was calculated as compared to adding MET in add-on group and switching from DPP4i in switch group, bP<0.05 from baseline in overall patients and each treatment subgroup, cP<0.05 for the between-treatment group difference.